Sundararaman Swaminathan

Sundararaman Swaminathan

Auto-generated profile, based on publicly available information

Sundararaman Swaminathan

Mayo Clinic Arizona USA; Department of Nephrology, Indian Institute of Science, Bengaluru, Karnataka, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MKMuhammad Ali Khan
Muhammad Ali Khan
MMMunir Mehmood
Munir Mehmood
HAHind EL Azzazi
Hind EL Azzazi
Samiullah ShaikhSamiullah Shaikh
Samiullah Shaikh
BBBhavna Bhasin-Chhabra
Bhavna Bhasin-Chhabra
BJBassam G. Abu Jawdeh
Bassam G. Abu Jawdeh
The indications for immune checkpoint inhibitor (ICI) use in cancer treatment continue to expand. This is attributable to their proven anticancer activity in addition to their tolerability and favorable toxicity profile as compared to conventional chemotherapeutic agents. ICIs work by blocking the inhibitory signals between tumor cells and T-cells, thereby enhancing the T-cell cytotoxic activity to inhibit tumor growth. Because of their immune-stimulating effect, ICIs are linked to adverse renal outcomes in both native and transplanted kidneys. The risk of kidney allograft rejection in the setting of ICI use has been reported to be around 40%, leading to an increased risk of graft loss. In this report, we review the literature examining outcomes in kidney transplant recipients receiving ICIs for various oncologic indications.

1 May 2024 in JMIR Medical Informatics
Verified
Journal Article
Open access
MCMaroun Chedid
Maroun Chedid
FCFouad Chebib
Fouad Chebib
EDErin Dahlen
Erin Dahlen
TMTheodore Mueller
Theodore Mueller
TSTheresa Schnell
Theresa Schnell
ZZZiad Zoghby
Ziad Zoghby
Background: Tolvaptan is the only US Food and Drug Administration–approved drug to slow the progression of autosomal dominant polycystic kidney disease (ADPKD), but it requires strict clinical monitoring due to potential serious adverse events. Objective: We aimed to share our experience in developing and implementing an electronic health record (EHR)–based application to monitor patients with ADPKD who were initiated on tolvaptan. Methods: The application was developed in collaboration with clinical informatics professionals based on our clinical protocol with frequent laboratory test monitoring to detect early drug-related toxicity. The application streamlined the clinical workflow and enabled our nursing team to take appropriate actions in real time to prevent drug-related serious adverse events. We retrospectively analyzed the characteristics of the enrolled patients. Results: As of September 2022, a total of 214 patients were enrolled in the tolvaptan program across all Mayo Clinic sites. Of these, 126 were enrolled in the Tolvaptan Monitoring Registry application and 88 in the Past Tolvaptan Patients application. The mean age at enrollment was 43.1 (SD 9.9) years. A total of 20 (9.3%) patients developed liver toxicity, but only 5 (2.3%) had to discontinue the drug. The 2 EHR-based applications allowed consolidation of all necessary patient information and real-time data management at the individual or population level. This approach facilitated efficient staff workflow, monitoring of drug-related adverse events, and timely prescription renewal. Conclusions: Our study highlights the feasibility of integrating digital applications into the EHR workflow to facilitate efficient and safe care delivery for patients enrolled in a tolvaptan program. This workflow needs further validation but could be extended to other health care systems managing chronic diseases requiring drug monitoring.

21 December 2025 in European Journal of Haematology
Verified
Journal Article
Closed access
ASAarti Sharma
Aarti Sharma
LPLatha Pathangey
Latha Pathangey
SCSinto Sebastian Chirackal
Sinto Sebastian Chirackal
KSKevin Guanwen Shim
Kevin Guanwen Shim
RFRafael Fonseca
Rafael Fonseca
SSSundararaman Swaminathan
Sundararaman Swaminathan

23 December 2025 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
ASAarti Sharma
Aarti Sharma
LPLatha Pathangey
Latha Pathangey
SCSinto Sebastian Chirackal
Sinto Sebastian Chirackal
KMKiran Kumar Mangalaparthi
Kiran Kumar Mangalaparthi
APAkhilesh Pandey
Akhilesh Pandey
SSSundararaman Swaminathan
Sundararaman Swaminathan
Impaired iron metabolism has been linked to the pathogenesis of multiple myeloma. Redox active iron chelators have gained attention as potential anti-cancer agents as they target the high iron dependency of cancer cells. This study explored the potential mechanisms underlying the anti-multiple myeloma effect of the redox active iron chelator Dp44mT (Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone). The effect of Dp44mT was tested on both immunomodulatory drug-sensitive and drug-resistant multiple myeloma cell lines using the MTT assay. Proteomic and phosphoproteomics characterization were utilized to explore the mechanisms of Dp44mT action on multiple myeloma cells. In addition, a real-time polymerase chain reaction assay was performed to examine the expressions of major iron metabolism genes. Reactive oxygen species, lipid peroxidation, mitochondrial membrane potential, and intracellular iron compartmentalization were measured using flow-cytometry. The high potency of Dp44mT in killing multiple myeloma cell lines was confirmed. Treatment with Dp44mT showed evidence of deregulated cellular iron metabolism, reactive oxygen species homeostasis, and mitochondrial membrane potential in multiple myeloma cell lines. As possible mechanistic pathways of Dp44mT, there was overrepresentation of the AMPK pathway, cell cycle, endoplasmic stress, and down regulation of ACSL4 (acyl-CoA synthetase long chain family member 4). This study suggests an in vitro, anti-multiple myeloma effect of Dp44mT that appears to be mediated by dysregulated iron metabolism, reactive oxygen species, and other biological pathways.

8 September 2025
Verified
Conference Paper
Open access
NBNarangerelt Batsoyol
Narangerelt Batsoyol
DWDaniel Waddington
Daniel Waddington
SSSwaminathan Sundararaman
Swaminathan Sundararaman
SSSteven Swanson
Steven Swanson